MedCity News March 11, 2022
Prenosis is aiming for FDA clearance this year for a diagnostic tool for sepsis, a condition that kills millions of people each year.
Prenosis has added a new investor as the precision medicine firm works toward regulatory approval for technology designed to give early warning of patients at risk of developing sepsis.
The new investor, PACE Healthcare Capital, brings the Chicago-based company’s fundraising total to more than $20 million. Prenosis did not disclose PACE’s investment or its other investors.
Like other startups, Prenosis is tapping into the power of artificial intelligence to develop a better picture of how diseases develop in patients. For Prenosis, the initial focus is sepsis, a life-threatening response to infection that kills 350,000 people each year...
Today's Sponsors
Today's Sponsor